tiprankstipranks
Oncolytics Biotech Posts Increased Q1 Loss
Company Announcements

Oncolytics Biotech Posts Increased Q1 Loss

Oncolytics Biotech (TSE:ONC) has released an update.

Oncolytics Biotech Inc. reports a net loss of $6,894 thousand for Q1 2024, a slight increase from $6,437 thousand in the same period last year. The company’s total assets decreased to $34,750 thousand as of March 31, 2024, from $38,820 thousand at the end of 2023, with a reduced cash position from $34,912 thousand to $29,603 thousand. Shareholders’ equity also saw a decline, dropping from $27,563 thousand to $22,969 thousand in the first quarter.

For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskOncolytics Biotech Advances Towards Drug Trial
TheFlyOncolytics announces ‘productive feedback’ from Type C meeting with FDA
TipRanks Canadian Auto-Generated NewsdeskOncolytics Biotech CEO Takes Medical Leave
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!